Groundbreaking: USA News about Novartis, Roche & AstraZeneca
Some in the USA rare disease community were wondering how this scenario would unfold - now we know. Well, at least…
aHUS Patients have a value beyond the balance sheet
It was little known, but Alexion decided years ago that it would reinvest 40% of any of its profits from the…